PMP22 and Charcot-Marie-Tooth disease type 1A: Current models of CMT1A tend to involve the use of either transgenic rodent models overexpressing PMP22 protein, subcultures from the rodent models, or CMT1A patient-derived human induced pluripotent stem cells (hiPSCs).